The estimated Net Worth of Tree Partners Ii Lp Apple is at least $7.05 Milion dollars as of 22 June 2018. Tree Apple owns over 106,257 units of Aileron Therapeutics Inc stock worth over $3,975,094 and over the last 7 years Tree sold ALRN stock worth over $3,076,764.
Tree has made over 7 trades of the Aileron Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Tree sold 106,257 units of ALRN stock worth $629,041 on 22 June 2018.
The largest trade Tree's ever made was selling 150,000 units of Aileron Therapeutics Inc stock on 9 January 2018 worth over $1,470,000. On average, Tree trades about 46,594 units every 18 days since 2017. As of 22 June 2018 Tree still owns at least 1,380,241 units of Aileron Therapeutics Inc stock.
You can see the complete history of Tree Apple stock trades at the bottom of the page.
Tree's mailing address filed with the SEC is 230 Park Ave #2800, New York, NY 10169, USA.
Over the last 14 years, insiders at Aileron Therapeutics Inc have traded over $6,473,296 worth of Aileron Therapeutics Inc stock and bought 16,658,005 units worth $51,661,886 . The most active insiders traders include Muneer A Satter, Bioventures Ltd Novartis Ag... a Armen Shanafelt. On average, Aileron Therapeutics Inc executives and independent directors trade stock every 77 days with the average trade being worth of $908,853. The most recent stock trade was executed by Of Texas/Texas Am Investmen... on 14 June 2024, trading 6,607 units of ALRN stock currently worth $21,539.
aileron is the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases. our lead product candidate, alrn-6924, which is being evaluated in multiple clinical trials, reactivates p53-mediated tumor suppression by targeting both of the primary p53 suppressor proteins mdmx and mdm2. the p53 protein, often referred to as the “guardian of the genome,” is known for its central role in preventing cancer initiation and progression, and its inactivation is essential for the formation of virtually all cancers. we believe that alrn-6924 is the first and only product candidate in clinical development that can inhibit both mdmx and mdm2, which we believe, based on published data and our preliminary clinical results, are equally important in restoring p53 function as the body’s first line of defense against cancer. based on preclinical data and preliminary evidence of safety and anti-tumor activity in our ongoing clinical trials, we believe there may be a sig
Aileron Therapeutics Inc executives and other stock owners filed with the SEC include: